Concepedia

Author

John T. Carpenter

University of Alabama at Birmingham

Also Known As

Carpenter, John, Gray, Joe W., Hope S. Rugo, J Carpenter, J T Carpenter, J. Carpenter, J. T. Carpenter, J.T. Carpenter, JOHN T. CARPENTER, John Carpenter

142

Publications

6.1K

Citations

26

H-Index

96

Concepts

All Affiliations

University of Alabama at BirminghamUniversity of AlabamaSidney Kimmel Comprehensive Cancer CenterIndiana University – Purdue University IndianapolisGeorgetown University
JT

About

John T. Carpenter is an author at University of Alabama at Birmingham specializing in medicine, oncology, and breast cancer.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

18

21

1.7K

2

Health Sciences

6

6

238

3

Arts

1

1

11

4

Nursing

1

1

102

5

Social Sciences

1

1

150

John T. Carpenter

×

34

Publications

5.5K

Citations

25

H-Index

YearCitations

Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741

Marc L. Citron, Donald A. Berry, Constance Cirrincione,

Journal of Clinical Oncology

2003

1.6K

Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer

I. Craig Henderson, Donald A. Berry, George D. Demetri,

Journal of Clinical Oncology

2003

1.3K

Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity.

Robert B. Diasio, T L Beavers, John T. Carpenter

Journal of Clinical Investigation

1988

499

Pathologic Complete Response Predicts Recurrence-Free Survival More Effectively by Cancer Subset: Results From the I-SPY 1 TRIAL—CALGB 150007/150012, ACRIN 6657

Laura J. Esserman, Donald A. Berry, Angela DeMichele,

Journal of Clinical Oncology

2012

435

Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome

Barry Harris, John T. Carpenter, Robert B. Diasio

Cancer

1991

223

Scoring Manual for the Thought Disorder Index

M. H. Johnston, P. S. Holzman, M. R. Solovay,

Schizophrenia Bulletin

1986

150

A comparison of cyclophosphamide, adriamycin, 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer.A southeastern cancer study group project

R V Smalley, John T. Carpenter, A Bartolucci,

Cancer

1977

127

A Randomized Prospective Trial of Radical (Halsted) Mastectomy Versus Modified Radical Mastectomy in 311 Breast Cancer Patients

William A. Maddox, John T. Carpenter, Henry L. Laws,

Annals of Surgery

1983

124

Weight gain with breast cancer adjuvant treatment

Ellen G. Levine, James M. Raczynski, John T. Carpenter

Cancer

1991

102

Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: implication for 5-fluorouracil-based chemotherapy.

Zhihong Lu, Ruiwen Zhang, John T. Carpenter,

PubMed

1998

101

Page 1